Engineered proteins to capture shed soluble TREM2 and facilitate membrane re-insertion or prevent proteolytic cleavage
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Surface TREM2 on Microglia Phagocytic Receptor"]
B["ADAM10 and ADAM17 Shedding Ectodomain Proteolytic Cleavage"]
C["Soluble TREM2 Released to CSF Non-Signaling Truncated Fragment"]
D["Microglial Surface TREM2 Depleted Reduced Phagocytic Signaling"]
E["Engineered Capture Proteins High Affinity sTREM2 Binding"]
F["Membrane Re-Insertion Facilitated or ADAM Shedding Prevented"]
G["Surface TREM2 Restored TYROBP-SYK Signaling Recovered"]
H["Microglial Phagocytic Capacity Amyloid Clearance Restored"]
A --> B
B --> C
B --> D
D -.->|"insufficient signaling"| H
C --> E
E --> F
F --> G
G --> H
style D fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMID5 mediumValidation: 0%5 supporting / 1 opposing
✓For(5)
5
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
3
MECH 3CLIN 0GENE 3EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
TREM2 macrophage promotes cardiac repair in myocar…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-06 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Based on the information gathered about TREM2, its protein interactions, and pathways, I'll now generate novel therapeutic hypotheses for targeting TREM2 in Alzheimer's disease following the INVOKE-2 failure:
Novel Therapeutic Hypotheses for TREM2 in Alzheimer's Disease
Hypothesis 1: TYROBP-SYK Pathway Enhancement
Title: Selective TYROBP stabilization to bypass TREM2 ectodomain loss
Description: Given TREM2's obligate partnership with TYROBP (DAP12) for signaling, developing small molecule stabilizers of the TYROBP-SYK complex could maintain downstream neuroprotective signali
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
I'll critically evaluate each of these TREM2 therapeutic hypotheses by examining their weaknesses, counter-evidence, and proposing falsifying experiments.
Critical Evaluation of TREM2 Therapeutic Hypotheses
Hypothesis 1: TYROBP-SYK Pathway Enhancement
Specific Weaknesses:
Assumes TYROBP-SYK signaling is universally beneficial, ignoring potential inflammatory consequences
Overlooks that TYROBP is shared with multiple immune receptors (not TREM2-specific)
No consideration of dose-response relationships or therapeutic window
Counter-evidence: The literature shows that exce
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Based on my analysis of the therapeutic hypotheses and available clinical data, here's my practical feasibility assessment:
PRACTICAL FEASIBILITY ASSESSMENT
HYPOTHESIS 1: TYROBP-SYK PATHWAY ENHANCEMENT
Druggability: MODERATE
Existing compounds: Fostamatinib (SYK inhibitor, FDA-approved for ITP)
Chemical matter: Multiple SYK inhibitors exist (fostamatinib, entospletinib, TAK-659)
Target validation: Strong - SYK is highly druggable kinase with validated inhibitors
Competitive Landscape:
Rigel Pharmaceuticals (fostamatinib) - established SYK franchise
M
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Based on the comprehensive debate between the Theorist, Skeptic, and Expert, I'll synthesize their inputs and produce final scored rankings. Let me analyze the evidence and score each hypothesis across the 10 dimensions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
💬 Discussion
Loading comments...
No DepMap CRISPR Chronos data found for ['TREM2'].
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
IF engineered TREM2-sequestration proteins (e.g., TREM2-Fc fusion with membrane-targeting domain) are applied to TREM2-expressing microglial cell cultures THEN membrane-associated TREM2 levels will increase by ≥50% (measured by surface biotinylation assay and flow cytometry) while soluble TREM2 in conditioned media will decrease by ≥40% within 48 hours using mouse BV-2 microglia or human iPSC-derived microglia
pendingconf: 0.75
Expected outcome: Increased surface TREM2 immunofluorescence intensity and Western blot signal from surface-biotinylated fractions; reduced sTREM2 concentration in media measured by ELISA
Falsified by: No significant change in membrane TREM2 levels OR no reduction in soluble TREM2 concentration indicates the engineered protein fails to capture and re-insert soluble TREM2, disproving the hypothesis
Method: BV-2 cells or iPSC-derived microglia will be treated with purified engineered TREM2-binding proteins (10 μg/mL). Surface proteins will be biotinylated, pulled down with streptavidin beads, and analyzed by Western blot with anti-TREM2 antibody. Soluble TREM2 in media will be quantified by ELISA. Controls include vehicle treatment and treatment with inactive(mutated) engineered protein.
IF engineered proteins designed to sterically block TREM2 cleavage sites (mutant TREM2-Fc with substrate-mimicking linker) are co-expressed with wild-type TREM2 in HEK293 cells THEN proteolytic cleavage of TREM2 will be reduced by ≥60% (measured by reduced sTREM2 fragment in media via Western blot and ELISA) compared to cells expressing TREM2 alone within 24 hours using HEK293 heterologous expression system
pendingconf: 0.70
Expected outcome: Significantly reduced intensity of ~20 kDa sTREM2 band in conditioned media Western blot; sTREM2 concentration <40% of control levels by ELISA
Falsified by: Equivalent or increased sTREM2 fragment generation in co-expression condition compared to TREM2-only control indicates the engineered protein cannot prevent proteolytic cleavage, disproving this aspect of the hypothesis
Method: HEK293 cells will be transfected with wild-type human TREM2 (pcDNA3.1) alone or co-transfected with the engineered cleavage-blocking protein. After 24 hours, conditioned media will be collected and sTREM2 will be immunoprecipitated with anti-TREM2 antibodies and analyzed by Western blot. Full-length TREM2 in cell lysates will serve as loading control. ADAM10/17 activity will be verified using a generic substrate assay to confirm non-specific toxicity is not the mechanism.
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
['TREM2'] — Search for structure
Click to search RCSB PDB